Skip to content

In the BioHarmony Drug Report Database

Ingenol mebutate

Picato (ingenol mebutate) is a small molecule pharmaceutical. Ingenol mebutate was first approved as Picato on 2012-01-23. It is used to treat actinic keratosis in the USA. The pharmaceutical is active against protein kinase C delta type. In addition, it is known to target protein kinase C epsilon type, protein kinase C alpha type, protein kinase C gamma type, and protein kinase C beta type. Picato's patents are valid until 2033-05-15 (FDA).
Trade Name Picato
Common Name Ingenol mebutate
Indication actinic keratosis
Drug Class
Ingenol mebutate
Get full access now